Proteins > Glutamate receptor ionotropic, NMDA 2A
Page last updated: 2024-08-07 17:03:46
Glutamate receptor ionotropic, NMDA 2A
A glutamate receptor ionotropic, NMDA 2A that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q12879]
Synonyms
GluN2A;
Glutamate [NMDA] receptor subunit epsilon-1;
N-methyl D-aspartate receptor subtype 2A;
NMDAR2A;
NR2A;
hNR2A
Research
Bioassay Publications (41)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (17.07) | 18.2507 |
2000's | 11 (26.83) | 29.6817 |
2010's | 16 (39.02) | 24.3611 |
2020's | 7 (17.07) | 2.80 |
Compounds (55)
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
6,7-dichloroquinoxaline-2,3-dione | Homo sapiens (human) | IC50 | 42,941.7533 | 2 | 3 |
tacrine | Homo sapiens (human) | IC50 | 25.8750 | 4 | 4 |
amantadine | Homo sapiens (human) | Ki | 10.5000 | 1 | 1 |
arcaine | Homo sapiens (human) | IC50 | 44.5550 | 2 | 2 |
chlorpromazine | Homo sapiens (human) | IC50 | 0.8500 | 2 | 2 |
racemethorphan | Homo sapiens (human) | IC50 | 0.3650 | 2 | 2 |
ifenprodil | Homo sapiens (human) | IC50 | 39.5000 | 1 | 1 |
ketamine | Homo sapiens (human) | IC50 | 3.5563 | 3 | 3 |
ketamine | Homo sapiens (human) | Ki | 0.5720 | 5 | 5 |
kynurenic acid | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
memantine | Homo sapiens (human) | IC50 | 3.6620 | 6 | 6 |
memantine | Homo sapiens (human) | Ki | 0.5400 | 2 | 2 |
methoctramine | Homo sapiens (human) | IC50 | 0.1380 | 1 | 1 |
orphenadrine | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
pentamidine | Homo sapiens (human) | IC50 | 0.7200 | 1 | 1 |
procyclidine | Homo sapiens (human) | Ki | 1.7000 | 1 | 1 |
phencyclidine | Homo sapiens (human) | IC50 | 0.2050 | 2 | 2 |
phencyclidine | Homo sapiens (human) | Ki | 0.0324 | 3 | 3 |
2,3-dihydroxyquinoxaline | Homo sapiens (human) | IC50 | 51,169.4000 | 2 | 2 |
glutamic acid | Homo sapiens (human) | IC50 | 0.0700 | 2 | 2 |
budipine | Homo sapiens (human) | Ki | 11.7000 | 1 | 1 |
6,7-dichloroquinoxaline-2,3-dione | Homo sapiens (human) | IC50 | 281,171.4000 | 2 | 2 |
ly 293558 | Homo sapiens (human) | IC50 | 12.1000 | 1 | 1 |
besonprodil | Homo sapiens (human) | IC50 | 0.0040 | 2 | 2 |
philanthotoxin 343 | Homo sapiens (human) | IC50 | 2.7390 | 1 | 1 |
dizocilpine | Homo sapiens (human) | IC50 | 0.0290 | 1 | 1 |
dizocilpine | Homo sapiens (human) | Ki | 0.0040 | 1 | 2 |
memantine hydrochloride | Homo sapiens (human) | IC50 | 2.3000 | 1 | 1 |
esketamine | Homo sapiens (human) | IC50 | 0.0114 | 1 | 1 |
cns 5161 | Homo sapiens (human) | Ki | 0.0019 | 1 | 1 |
cp 101,606 | Homo sapiens (human) | IC50 | 0.0070 | 1 | 1 |
cp 101,606 | Homo sapiens (human) | Ki | 0.0110 | 1 | 1 |
dexoxadrol | Homo sapiens (human) | IC50 | 0.0097 | 1 | 1 |
dexoxadrol | Homo sapiens (human) | Ki | 0.0190 | 1 | 1 |
7-chloro-thiokynurenate | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
tcn 201 | Homo sapiens (human) | IC50 | 0.2198 | 4 | 4 |
l 745870 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
levorphanol | Homo sapiens (human) | IC50 | 2.6000 | 2 | 2 |
dextromethorphan | Homo sapiens (human) | Ki | 1.6800 | 1 | 1 |
dextrorphan | Homo sapiens (human) | IC50 | 1.3000 | 1 | 1 |
dextrorphan | Homo sapiens (human) | Ki | 0.2200 | 1 | 1 |
licostinel | Homo sapiens (human) | IC50 | 2,944.2230 | 2 | 2 |
ro 25-6981 | Homo sapiens (human) | IC50 | 17.3373 | 3 | 3 |
ro 25-6981 | Homo sapiens (human) | Ki | 0.0058 | 2 | 2 |
eaa-090 | Homo sapiens (human) | IC50 | 3.8150 | 2 | 2 |
pd 174494 | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
fpl 15896ar | Homo sapiens (human) | Ki | 0.5600 | 1 | 1 |
(4-benzylpiperidin-1-yl)-(6-hydroxy-1h-indol-2-yl)methanone | Homo sapiens (human) | IC50 | 0.0120 | 1 | 1 |
tqx 173 | Homo sapiens (human) | IC50 | 46.0000 | 1 | 1 |
(1rs,1's)-peaqx | Homo sapiens (human) | IC50 | 0.1390 | 2 | 2 |
etoxadrol | Homo sapiens (human) | Ki | 0.0220 | 1 | 1 |
methoxydine | Homo sapiens (human) | IC50 | 3.9811 | 1 | 1 |
nitd 609 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
Drugs with Activation Measurements
Drugs with Other Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
licostinel | Homo sapiens (human) | Kb | 0.0050 | 1 | 1 |
Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-d-Aspartate receptors.European journal of medicinal chemistry, , Jul-05, Volume: 219, 2021
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.Journal of medicinal chemistry, , Aug-27, Volume: 58, Issue:16, 2015
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.Journal of medicinal chemistry, , May-13, Volume: 53, Issue:9, 2010
Repurposing of Drugs-The Ketamine Story.Journal of medicinal chemistry, , 11-25, Volume: 63, Issue:22, 2020
Ketamine esters and amides as short-acting anaesthetics: Structure-activity relationships for the side-chain.Bioorganic & medicinal chemistry, , 04-01, Volume: 27, Issue:7, 2019
Some non-conventional biomolecular targets for diamidines. A short survey.Bioorganic & medicinal chemistry, , Apr-01, Volume: 22, Issue:7, 2014
Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 21, Issue:7, 2011
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.Journal of medicinal chemistry, , May-13, Volume: 53, Issue:9, 2010
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.Bioorganic & medicinal chemistry, , 09-15, Volume: 46, 2021
Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.European journal of medicinal chemistry, , May-15, Volume: 194, 2020
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.Journal of medicinal chemistry, , Aug-27, Volume: 58, Issue:16, 2015
Some non-conventional biomolecular targets for diamidines. A short survey.Bioorganic & medicinal chemistry, , Apr-01, Volume: 22, Issue:7, 2014
In vitro and in vivo evaluation of polymethylene tetraamine derivatives as NMDA receptor channel blockers.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 23, Issue:13, 2013
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.Journal of medicinal chemistry, , May-13, Volume: 53, Issue:9, 2010
Design, synthesis, and biological evaluation of tricyclic heterocycle-tetraamine conjugates as potent NMDA channel blockers.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 17, Issue:17, 2007
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.European journal of medicinal chemistry, , May-15, Volume: 194, 2020
Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring.Journal of medicinal chemistry, , Nov-12, Volume: 58, Issue:21, 2015
Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 21, Issue:7, 2011
Methylated analogues of methyl (R)-4-(3,4-dichlorophenylacetyl)- 3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (GR-89,696) as highly potent kappa-receptor agonists: stereoselective synthesis, opioid-receptor affinity, receptor selectivity, and functioJournal of medicinal chemistry, , Aug-16, Volume: 44, Issue:17, 2001
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
SAGE-718: A First-in-Class Journal of medicinal chemistry, , 07-14, Volume: 65, Issue:13, 2022
Neuroactive Steroid Journal of medicinal chemistry, , 08-22, Volume: 62, Issue:16, 2019
(3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist.Journal of medicinal chemistry, , Jul-09, Volume: 36, Issue:14, 1993
Oxamides as novel NR2B selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Aug-02, Volume: 14, Issue:15, 2004
Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Nov-03, Volume: 13, Issue:21, 2003
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 21, Issue:11, 2011
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
Oxamides as novel NR2B selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Aug-02, Volume: 14, Issue:15, 2004
2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Mar-10, Volume: 13, Issue:5, 2003
Some non-conventional biomolecular targets for diamidines. A short survey.Bioorganic & medicinal chemistry, , Apr-01, Volume: 22, Issue:7, 2014
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
CoMFA and homology-based models of the glycine binding site of N-methyl-d-aspartate receptor.Journal of medicinal chemistry, , Apr-24, Volume: 46, Issue:9, 2003
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.Journal of medicinal chemistry, , Nov-25, Volume: 37, Issue:24, 1994
Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.Journal of medicinal chemistry, , 01-10, Volume: 62, Issue:1, 2019
Oxamides as novel NR2B selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Aug-02, Volume: 14, Issue:15, 2004
Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Nov-03, Volume: 13, Issue:21, 2003
2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.Bioorganic & medicinal chemistry letters, , Mar-10, Volume: 13, Issue:5, 2003
Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist.Bioorganic & medicinal chemistry letters, , Aug-20, Volume: 11, Issue:16, 2001
Enables
This protein enables 6 target(s):
Target | Category | Definition |
amyloid-beta binding | molecular function | Binding to an amyloid-beta peptide/protein. [GOC:hjd] |
NMDA glutamate receptor activity | molecular function | An cation channel that opens in response to binding by extracellular glutmate, but only if glycine is also bound and the membrane is depolarized. Voltage gating is indirect, due to ejection of bound magnesium from the pore at permissive voltages. [GOC:mah, PMID:10049997] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
zinc ion binding | molecular function | Binding to a zinc ion (Zn). [GOC:ai] |
glutamate-gated calcium ion channel activity | molecular function | Enables the transmembrane transfer of a calcium ion by a channel that opens when glutamate has been bound by the channel complex or one of its constituent parts. [GOC:mtg_transport, ISBN:0815340729] |
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential | molecular function | Any transmitter-gated ion channel activity that is involved in regulation of postsynaptic membrane potential. [GO_REF:0000061, GOC:TermGenie, PMID:20200227] |
Located In
This protein is located in 11 target(s):
Target | Category | Definition |
endoplasmic reticulum membrane | cellular component | The lipid bilayer surrounding the endoplasmic reticulum. [GOC:mah] |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
synaptic vesicle | cellular component | A secretory organelle, typically 50 nm in diameter, of presynaptic nerve terminals; accumulates in high concentrations of neurotransmitters and secretes these into the synaptic cleft by fusion with the 'active zone' of the presynaptic plasma membrane. [PMID:10099709, PMID:12563290] |
cell surface | cellular component | The external part of the cell wall and/or plasma membrane. [GOC:jl, GOC:mtg_sensu, GOC:sm] |
postsynaptic density | cellular component | An electron dense network of proteins within and adjacent to the postsynaptic membrane of an asymmetric, neuron-neuron synapse. Its major components include neurotransmitter receptors and the proteins that spatially and functionally organize them such as anchoring and scaffolding molecules, signaling enzymes and cytoskeletal components. [GOC:BHF, GOC:dos, GOC:ef, GOC:jid, GOC:pr, GOC:sjp, http://molneuro.kaist.ac.kr/psd, PMID:14532281, Wikipedia:Postsynaptic_density] |
cytoplasmic vesicle membrane | cellular component | The lipid bilayer surrounding a cytoplasmic vesicle. [GOC:mah] |
presynaptic membrane | cellular component | A specialized area of membrane of the axon terminal that faces the plasma membrane of the neuron or muscle fiber with which the axon terminal establishes a synaptic junction; many synaptic junctions exhibit structural presynaptic characteristics, such as conical, electron-dense internal protrusions, that distinguish it from the remainder of the axon plasma membrane. [GOC:jl, ISBN:0815316194] |
dendritic spine | cellular component | A small, membranous protrusion from a dendrite that forms a postsynaptic compartment, typically receiving input from a single presynapse. They function as partially isolated biochemical and an electrical compartments. Spine morphology is variable:they can be thin, stubby, mushroom, or branched, with a continuum of intermediate morphologies. They typically terminate in a bulb shape, linked to the dendritic shaft by a restriction. Spine remodeling is though to be involved in synaptic plasticity. [GOC:nln] |
postsynaptic membrane | cellular component | A specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft). Neurotransmitters cross the synaptic cleft and transmit the signal to the postsynaptic membrane. [ISBN:0198506732] |
synaptic membrane | cellular component | A specialized area of membrane on either the presynaptic or the postsynaptic side of a synapse, the junction between a nerve fiber of one neuron and another neuron or muscle fiber or glial cell. [GOC:BHF, PMID:20410104] |
glutamatergic synapse | cellular component | A synapse that uses glutamate as a neurotransmitter. [GOC:dos] |
Active In
This protein is active in 2 target(s):
Target | Category | Definition |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
postsynaptic density membrane | cellular component | The membrane component of the postsynaptic density. This is the region of the postsynaptic membrane in which the population of neurotransmitter receptors involved in synaptic transmission are concentrated. [GOC:dos] |
Part Of
This protein is part of 1 target(s):
Target | Category | Definition |
NMDA selective glutamate receptor complex | cellular component | An assembly of four or five subunits which form a structure with an extracellular N-terminus and a large loop that together form the ligand binding domain. The C-terminus is intracellular. The ionotropic glutamate receptor complex itself acts as a ligand gated ion channel; on binding glutamate, charged ions pass through a channel in the center of the receptor complex. NMDA receptors are composed of assemblies of NR1 subunits (Figure 3) and NR2 subunits, which can be one of four separate gene products (NR2A-D). Expression of both subunits are required to form functional channels. The glutamate binding domain is formed at the junction of NR1 and NR2 subunits. NMDA receptors are permeable to calcium ions as well as being permeable to other ions. Thus NMDA receptor activation leads to a calcium influx into the post-synaptic cells, a signal thought to be crucial for the induction of NMDA-receptor dependent LTP and LTD. [http://www.bris.ac.uk/Depts/Synaptic/info/glutamate.html] |
Involved In
This protein is involved in 35 target(s):
Target | Category | Definition |
startle response | biological process | An action or movement due to the application of a sudden unexpected stimulus. [GOC:dph] |
response to amphetamine | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amphetamine stimulus. Amphetamines consist of a group of compounds related to alpha-methylphenethylamine. [GOC:dph, GOC:ef] |
glutamate receptor signaling pathway | biological process | The series of molecular signals initiated by the binding of glutamate to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:mah, GOC:signaling, PMID:9131252] |
chemical synaptic transmission | biological process | The vesicular release of classical neurotransmitter molecules from a presynapse, across a chemical synapse, the subsequent activation of neurotransmitter receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse. [GOC:jl, MeSH:D009435] |
brain development | biological process | The process whose specific outcome is the progression of the brain over time, from its formation to the mature structure. Brain development begins with patterning events in the neural tube and ends with the mature structure that is the center of thought and emotion. The brain is responsible for the coordination and control of bodily activities and the interpretation of information from the senses (sight, hearing, smell, etc.). [GOC:dph, GOC:jid, GOC:tb, UBERON:0000955] |
learning or memory | biological process | The acquisition and processing of information and/or the storage and retrieval of this information over time. [GOC:jid, PMID:8938125] |
memory | biological process | The activities involved in the mental information processing system that receives (registers), modifies, stores, and retrieves informational stimuli. The main stages involved in the formation and retrieval of memory are encoding (processing of received information by acquisition), storage (building a permanent record of received information as a result of consolidation) and retrieval (calling back the stored information and use it in a suitable way to execute a given task). [GOC:curators, ISBN:0582227089] |
visual learning | biological process | Any process in an organism in which a change in behavior of an individual occurs in response to repeated exposure to a visual cue. [GOC:jid, ISBN:0582227089] |
response to xenobiotic stimulus | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
response to wounding | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to the organism. [GOC:go_curators] |
sensory perception of pain | biological process | The series of events required for an organism to receive a painful stimulus, convert it to a molecular signal, and recognize and characterize the signal. Pain is medically defined as the physical sensation of discomfort or distress caused by injury or illness, so can hence be described as a harmful stimulus which signals current (or impending) tissue damage. Pain may come from extremes of temperature, mechanical damage, electricity or from noxious chemical substances. This is a neurological process. [GOC:curators] |
calcium-mediated signaling | biological process | Any intracellular signal transduction in which the signal is passed on within the cell via calcium ions. [GOC:signaling] |
neurogenesis | biological process | Generation of cells within the nervous system. [GO_REF:0000021, GOC:cls, GOC:curators, GOC:dgh, GOC:dph, GOC:jid] |
protein catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds. [GOC:mah] |
sleep | biological process | Any process in which an organism enters and maintains a periodic, readily reversible state of reduced awareness and metabolic activity. Usually accompanied by physical relaxation, the onset of sleep in humans and other mammals is marked by a change in the electrical activity of the brain. [ISBN:0192800981] |
directional locomotion | biological process | Self-propelled movement of a cell or organism from one location to another along an axis. [GOC:mtg_MIT_16mar07] |
ionotropic glutamate receptor signaling pathway | biological process | The series of molecular signals initiated by glutamate binding to a glutamate receptor on the surface of the target cell, followed by the movement of ions through a channel in the receptor complex, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:signaling, ISBN:0198506732] |
negative regulation of protein catabolic process | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of protein catabolic process. [GO_REF:0000058, GOC:kmv, GOC:obol, GOC:TermGenie, PMID:24785082] |
dopamine metabolic process | biological process | The chemical reactions and pathways involving dopamine, a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline. [GOC:jl, ISBN:0198506732] |
serotonin metabolic process | biological process | The chemical reactions and pathways involving serotonin (5-hydroxytryptamine), a monoamine neurotransmitter occurring in the peripheral and central nervous systems, also having hormonal properties. [GOC:jl, ISBN:0198506732] |
positive regulation of apoptotic process | biological process | Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. [GOC:jl, GOC:mtg_apoptosis] |
response to ethanol | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethanol stimulus. [GOC:go_curators] |
regulation of synaptic plasticity | biological process | A process that modulates synaptic plasticity, the ability of synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers. [GOC:dph, GOC:jid, GOC:tb, PMID:11891290] |
regulation of neuronal synaptic plasticity | biological process | A process that modulates neuronal synaptic plasticity, the ability of neuronal synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers. [GOC:jid, PMID:11891290] |
positive regulation of synaptic transmission, glutamatergic | biological process | Any process that activates, maintains or increases the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate. [GOC:ai] |
activation of cysteine-type endopeptidase activity | biological process | Any process that initiates the activity of the inactive enzyme cysteine-type endopeptidase. [GOC:mtg_apoptosis, PMID:21726810] |
calcium ion transmembrane import into cytosol | biological process | A process in which a calcium ion is transported from one side of a membrane to the other into the cytosol by means of some agent such as a transporter or pore. [GOC:vw] |
monoatomic cation transmembrane transport | biological process | The process in which a monoatomic cation is transported across a membrane. Monatomic cations (also called simple cations) are positively charged ions consisting of exactly one atom. [GOC:dos, GOC:vw] |
excitatory chemical synaptic transmission | biological process | Synaptic transmission that results in an excitatory postsynaptic potential. [GOC:dos] |
protein localization to postsynaptic membrane | biological process | A process in which a protein is transported to, or maintained in, a location within a postsynaptic membrane. [GO_REF:0000087, GOC:kmv, GOC:TermGenie, PMID:9753322] |
regulation of monoatomic cation transmembrane transport | biological process | Any process that modulates the frequency, rate or extent of cation transmembrane transport. [GO_REF:0000058, GOC:TermGenie, PMID:15304482] |
positive regulation of excitatory postsynaptic potential | biological process | Any process that enhances the establishment or increases the extent of the excitatory postsynaptic potential (EPSP) which is a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential. [GOC:bf, GOC:BHF] |
synaptic transmission, glutamatergic | biological process | The vesicular release of glutamate from a presynapse, across a chemical synapse, the subsequent activation of glutamate receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse. [GOC:dos] |
excitatory postsynaptic potential | biological process | A process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential. [GOC:dph, GOC:ef] |
long-term synaptic potentiation | biological process | A process that modulates synaptic plasticity such that synapses are changed resulting in the increase in the rate, or frequency of synaptic transmission at the synapse. [GOC:dgh, GOC:dph] |